Abstract
The selective action of a replication-competent, E1B-deficient adenovirus therapy for cancer is challenged in a new study (pages 1068–1072).
This is a preview of subscription content, log in via an institution to check access.
References
Bischoff, J.R. et al. An adenovirus mutant that replicates selectively in p53-deficient tumor cells. Science 274, 373– 376 (1996).
Heise, C. et al. ONYX-015, an E1B gene-attenuated adenovirus causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Med. 6, 639– 645 (1997).
Hall, A.R. et al. p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nature Med. 4, 1068 –1072 (1998).
Roa et al. Proc.Natl.Acad.Sci. U.S.A. 89, 7742–7746 ( 1992).
Barker, D.D. & Berk, A.J. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 156, 107– 121 (1987).
Dobner, T. et al. Blockage by adenovirus E4ORF6 of transcriptional activation by the p53 tumor suppressor. Science 272, 1470 –1473 (1996).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lane, D. Killing tumor cells with viruses—a question of specificity. Nat Med 4, 1012–1013 (1998). https://doi.org/10.1038/2000
Issue Date:
DOI: https://doi.org/10.1038/2000
- Springer Nature America, Inc.
This article is cited by
-
Human papillomavirus therapy for the prevention and treatment of cervical cancer
Current Treatment Options in Oncology (2003)
-
Assessment of growth inhibition and morphological changes in in vitro and in vivo hepatocellular carcinoma models post treatment with dl1520 adenovirus
Cancer Gene Therapy (2002)
-
Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression
Gene Therapy (2000)
-
ONYX-015: Clinical data are encouraging
Nature Medicine (1998)